Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Carcinoma, Renal Cell 30Carcinoma, Non-Small-Cell Lung 16Melanoma 15Prostatic Neoplasms 13Stomach Neoplasms 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 9Kidney Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Neoplasms 7Neoplasm Metastasis 6Lung Neoplasms 6Breast Neoplasms 6Ovarian Neoplasms 5Carcinoma, Merkel Cell 5Urologic Neoplasms 4Pancreatic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Neuroendocrine Tumors 2

Interventions

pembrolizumab 4poly ICLC 1osimertinib 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1Vorinostat 1Taxes 1Pemetrexed 1Paclitaxel 1Nivolumab 1High-Intensity Focused Ultrasound Ablation 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × atezolizumab × Genitourinary × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡